Prognostic significance of CD4/CD8 ratio in patients with advanced cervical cancer

Abstract

Cervical cancer is caused by HPV infection, which types mainly 16,18,31, and 45. CD4+ T cells are the most important cells in viral clearance. CD4+ and CD8+ are involved in the apoptotic process and the CD4/CD8 ratio was assessed in response to the treatment of NAC in advanced cervical cancer. We conducted a case-control study with 30 patients of advanced cervical cancer and 30 patients as the control. Samples were taken from the vein and processed using hemocytometry. Samples were checked three times for cases when the stage of cervical cancer was enforced, before patients underwent 2nd and 3rd series of NAC. The majority of controls were 39.73 years and for the cases were 48.3 years. Patients with CD4/CD8 ratio ≥ 1.2069 had 1.5 times higher risk to cervical cancer than patients with CD4/CD8 ratio < 1.2069, but it was insignificant (OR = 1.495, 95% CI = 0.540-4.136, p = 0.605). Before therapy, they had lower CD4 and CD8 value compared to control. The higher the CD4/CD8 ratio before the 3rd series of NAC was, the higher the risk of having no response towards NAC treatment in advanced cervical cancer patients. Moreover, most of our patients had either complete or partial response.